MAI Capital Management’s Cytek Biosciences CTKB Stock Holding History

MAI Capital Management’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-78	Closed	-$341	–	2648
2026 Q1	$341	Buy	+78	New	+$368	﹤0.01%	4504

Other funds holding CTKB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

MAI Capital Management's CTKB Position: Q2 2026 in Review

MAI Capital Management sold out of Cytek Biosciences (CTKB) in Q2 2026, closing a stake of 78 shares — an estimated $341 sold.

MAI Capital Management first reported a position in CTKB in Q1 2026 and held it in 1 quarter. The position peaked at $341 in Q1 2026. 154 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

MAI Capital Management reported no remaining Cytek Biosciences position as of Q2 2026 after selling out during the quarter.
MAI Capital Management sold 78 Cytek Biosciences shares in Q2 2026, an estimated $341.
MAI Capital Management first reported a position in Cytek Biosciences in Q1 2026 and held it in 1 quarter.
MAI Capital Management's Cytek Biosciences position peaked at $341 in Q1 2026.
154 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.